Canaccord Genuity Maintains Buy on Pulmonx, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Jon Young maintains a Buy rating on Pulmonx (NASDAQ:LUNG) and raises the price target from $15 to $16.
August 01, 2024 | 2:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst Jon Young maintains a Buy rating on Pulmonx and raises the price target from $15 to $16.
The raised price target and maintained Buy rating from a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100